Prostate cancer
Conditions
Interventions
Cohort A: Treatment group:prostate and metastatic full coverage radiotherapy group (TRT)
Cohort B: Control group:prostate radiotherapy group (PRT)
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1) 18 -85 years old. 2) Pathologically confirmed prostate cancer, except small cell carcinoma or sarcoma, is allowed to contain partial neuroendocrine differentiation. 3) New generation imaging such as prostate specific membrane antigen (PSMA) PET=10 metastases. Non-regional lymph node metastasis was allowed. Pelvic lymph node metastases (N1) were allowed but not counted as metastases. The pelvis is divided into four parts according to anatomy: the left hip bone, the right hip bone, the sacrum, and the tailbone. If there are multiple metastases in each part, the total number of each part is 1. The following picture shows two metastases (left hip bone and sacrum). 4) Systemic therapy (endocrine therapy, chemotherapy, targeted therapy, and nuclide therapy) was allowed before enrollment, with the randomization time =3 months. 5) ECOG score 0-2. 6) Agree to join the group and sign the informed consent. 7) Can cooperate with radiotherapy position fixation and radiotherapy. 8) Able to cooperate with the completion of quality of life related questionnaires.
Exclusion criteria
Exclusion criteria: 1) External radiotherapy, brachytherapy and radical prostatectomy were performed on the primary site. 2) Hormone resistance stage (mCRPC). 3) Participants considered unsuitable for clinical trials by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Complete PSA response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Time to PSA Progression;Toxic side effects;Quality of life;Time to Next Intervention; | — |
Countries
China
Contacts
Public ContactQi Xin
Peking University First Hospital
Outcome results
None listed